SARS‐CoV‐2 infection during pregnancy is associated with adverse maternal and neonatal
outcomes, but no systematic synthesis of evidence on COVID‐19 vaccination during …

Background Infants< 3 months of age are at highest risk for developing severe complications
after pertussis. The majority of pregnant women has low concentrations of pertussis-specific …

Background Respiratory syncytial virus (RSV), a major cause of illness and death in infants
worldwide, could be prevented by vaccination during pregnancy. The efficacy …

Importance There is limited comparative epidemiological evidence on outcomes associated
with COVID-19 vaccination during pregnancy; monitoring pregnancy outcomes in large …

Background Protection against human respiratory syncytial virus (RSV) remains an unmet
need potentially addressable by maternal immunization. This phase 1/2 study evaluated a …

We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in
30,311 infants born at Kaiser Permanente Northern California from December 15, 2020, to …

Pediatric vaccines have significantly reduced infectious disease–related infant mortality, but
as protective immunity often requires several infant vaccine doses, maternally acquired Abs …

Background Infants aged< 1 year are at highest risk for pertussis-related morbidity and
mortality. In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) …

Introduction Infants too young to be fully immunized are the most vulnerable to severe
pertussis disease. To close this susceptibility gap, passive infant immunization through …

Immunization during pregnancy has been recommended in an increasing number of
countries. The aim of this strategy is to protect pregnant women and infants from severe …